4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3015% below fair value
$10.46−0.33 (-3.06%)
Close on Nov 18, 2026Market cap $755.00MP/E –Yield –
4D Molecular Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
4D Molecular Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$109.62M. For fiscal 2025 it was -$109.62M. The highest annual figure on record is -$39.91M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$109.62M | – |
| FY2024 | Dec 31, 2024 | -$138.37M | – |
| FY2023 | Dec 31, 2023 | -$78.56M | – |
| FY2022 | Dec 31, 2022 | -$98.22M | – |
| FY2021 | Dec 31, 2021 | -$78.24M | – |
| FY2020 | Dec 31, 2020 | -$51.91M | – |
| FY2019 | Dec 31, 2019 | -$39.91M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $28.62M | – |
| Q3 FY2025 | Sep 30, 2025 | -$46.41M | – |
| Q2 FY2025 | Jun 30, 2025 | -$43.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$48.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$46.81M | – |
| Q3 FY2024 | Sep 30, 2024 | -$31.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.58M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.92M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.98M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$29.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.93M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.94M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.01M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.01M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.29M | – |
| Q1 FY2020 | Mar 31, 2020 | -$14.59M | – |
See a number that looks wrong?